For patients

IL-17 inhibitors

secukinumab, ixekizumab, bimekizumab, anti-IL-17

Are you a clinician? See the clinical version of this page.

The short versionIL-17 inhibitors (used for psoriatic arthritis and axial spondyloarthritis) may be continued in pregnancy if needed to control your disease, based on a shared decision, since the data are still limited. Breastfeeding data are more limited, so discuss timing with your team.

Through your pregnancy journey

Use if needed

Before pregnancy

May be continued if needed for disease control; discuss with your team.

Use if needed

First trimester

Used if needed for disease control.

Use if needed

Second & third trimester

Used if needed for disease control.

Use if needed

Breastfeeding

Breastfeeding data are limited; large antibodies transfer minimally into milk. Discuss with your team.

Continue

For fathers-to-be

Considered compatible for fathers-to-be.

iThis page helps you prepare a conversation with your care team. It does not replace individual medical advice. Always confirm your own plan with your rheumatology and pregnancy team.
!

When to call your team